Welcome to our dedicated page for Intuitive Surgical news (Ticker: ISRG), a resource for investors and traders seeking the latest updates and insights on Intuitive Surgical stock.
Intuitive Surgical Inc. (NASDAQ: ISRG), the pioneer of robotic-assisted minimally invasive surgery, provides critical updates through this comprehensive news hub. Track the latest developments surrounding the da Vinci Surgical System, regulatory milestones, and strategic initiatives shaping the future of surgical care.
This resource delivers verified press releases and financial updates essential for understanding ISRG's market position. Investors gain insights into earnings reports, partnership announcements, and technology advancements while medical professionals stay informed about clinical applications and procedural innovations.
Key content includes quarterly financial results, FDA clearances for new instruments, global expansion updates, and research collaborations advancing robotic surgery. All materials are sourced from official channels to ensure accuracy and compliance with financial disclosure standards.
Bookmark this page for real-time access to ISRG's evolving role in healthcare technology. Combine strategic awareness with operational knowledge through our curated collection of company-verified information.
Intuitive announced FDA clearance for the SureForm 30 Curved-Tip Stapler, an 8 mm device aimed at enhancing surgical access in various procedures. Set to launch in 2022, this stapler features a 120-degree articulation and integrates SmartFire technology for optimized staple line performance. The tool allows better visualization for surgeons, which can be crucial in complex surgeries. The company is committed to innovating through customer feedback to improve surgical instruments. The launch is anticipated to bolster Intuitive's portfolio in robotic-assisted surgery.
Intuitive Surgical (Nasdaq: ISRG) has reached a significant milestone by surpassing 10 million robotic-assisted surgical procedures performed with its da Vinci surgical systems. This achievement underscores the growing adoption of minimally invasive surgery worldwide, with over 6,500 da Vinci systems installed in 67 countries and more than 55,000 trained surgeons. CEO Gary Guthart emphasized the commitment to continuous innovation, personalized training programs, and enhancing patient outcomes while addressing over 30,000 clinical studies supporting the technology.
Intuitive (Nasdaq: ISRG) announces key executive leadership changes aimed at supporting its growth and advancing minimally invasive care globally. Effective January 1, 2022, Marshall Mohr takes on the role of Executive Vice President for Global Business Services, with Jamie Samath succeeding him as Chief Financial Officer. Dave Rosa is appointed Chief Strategy and Growth Officer, and Henry Charlton becomes Chief Commercial Officer. These appointments reflect a strategic alignment within the company, focusing on operational efficiency, growth opportunities, and enhanced decision-making processes to better serve customers.
Intuitive (Nasdaq: ISRG) reported Q3 2021 financial results, highlighting a 30% increase in revenue to $1.40 billion compared to Q3 2020. The number of da Vinci systems shipped rose 72% to 336, and the total installed base increased to 6,525 systems. Net income reached $381 million ($1.04 per diluted share), up from $314 million in the same quarter last year. The company's cash and investments totaled $8.2 billion, indicating strong operational cash generation.
Intuitive announced preliminary data from the PRECIsE trial, a post-market evaluation of its Ion endoluminal system, at the CHEST conference. The system achieved an 83% diagnostic yield for pulmonary nodule biopsies across 69 subjects, with 82% for nodules 1-2 cm and 85% for 2-3 cm. The Ion system reported no serious adverse events and a sensitivity for malignancy ranging from 84% to 88%. This trial involves a total of 365 patients, beginning enrollment in March 2019. Currently, over 70 Ion systems are installed in U.S. hospitals.
Intuitive (Nasdaq: ISRG) announces the appointment of Yong-Bum Choi as the new General Manager for South Korea, tasked with enhancing business strategy and operations in a key market for minimally invasive care. Choi brings over 26 years of healthcare experience from companies like Janssen and Eli Lilly, strengthening Intuitive's leadership in robotic-assisted surgery. Since entering South Korea in 2005, Intuitive has installed over 110 systems and facilitated more than 190,000 surgeries, positioning it for further growth under Choi's guidance.
Intuitive (Nasdaq: ISRG) announced a proposed three-for-one stock split pending shareholder approval. The Amendment to the Company’s Certificate of Incorporation is set for a vote at the Special Meeting on September 20, 2021. If approved, stockholders of record on September 27, 2021 will receive two additional shares for every share held, with trading expected to start on a split-adjusted basis on October 5, 2021. This move aims to enhance liquidity and accessibility for investors.
Intuitive (Nasdaq: ISRG) reported strong financial results for Q2 2021, with revenues of $1.46 billion, up 72% from $0.85 billion in Q2 2020. This growth is attributed to a 68% increase in da Vinci procedures and a significant rise in system shipments, totaling 328 units—an 84% increase year-over-year. GAAP net income reached $517 million, or $4.25 per diluted share, compared to $68 million a year earlier. The company ended the quarter with $7.7 billion in cash and investments, reflecting solid operational cash generation and recovery from pandemic-related disruptions.
Intuitive (Nasdaq: ISRG) announced the appointment of Dr. Monica P. Reed to its board of directors, effective April 22, 2021. Dr. Reed, a former executive at AdventHealth, has over 30 years of experience in healthcare leadership, including serving as chief medical officer and CEO at AdventHealth. Her extensive background in hospital administration is expected to enhance Intuitive's strategic direction in robotic-assisted surgery. CEO Gary Guthart expressed optimism about her contributions to improving service to surgeons and healthcare systems.
Intuitive (Nasdaq: ISRG) reported strong Q1 2021 results, with revenue reaching $1.29 billion, marking an 18% increase year-over-year. The company shipped 298 da Vinci Surgical Systems, a 26% rise from last year, and achieved an installed base of 6,142 systems, up 8%. GAAP net income also grew to $426 million ($3.51 per diluted share), compared to $314 million ($2.62 per diluted share) in Q1 2020. Instruments and accessories revenue rose 14% to $706 million, driven by a 16% increase in da Vinci procedure volume.
